PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab

To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and measured Lp(a) secretion from human hepatocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Villard, Elise F., Thedrez, Aurélie, Blankenstein, Jorg, Croyal, Mikaël, Tran, Thi-Thu-Trang, Poirier, Bruno, Le Bail, Jean-Christophe, Illiano, Stéphane, Nobécourt, Estelle, Krempf, Michel, Blom, Dirk J., Marais, A. David, Janiak, Philip, Muslin, Anthony J., Guillot, Etienne, Lambert, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753417/
https://www.ncbi.nlm.nih.gov/pubmed/29308438
http://dx.doi.org/10.1016/j.jacbts.2016.06.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753417/
https://www.ncbi.nlm.nih.gov/pubmed/29308438
http://dx.doi.org/10.1016/j.jacbts.2016.06.006

Ejemplares similares